Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection

• Published in: Journal of neuroimmunology Vol. 361; p. 577739
• Main Authors: Dias da Costa, Mariana, Leal Rato, Miguel, Cruz, Diana, Valadas, Anabela, Antunes, Ana Patrícia, Albuquerque, Luísa
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.12.2021; Elsevier
• Subjects: Adult; Autoantibodies - immunology; Autoantigens - immunology; COVID-19; COVID-19 - complications; COVID-19 - immunology; Humans; Male; MOG-IgG; Myelin-Oligodendrocyte Glycoprotein - immunology; Myelitis; Myelitis, Transverse - immunology; Myelitis, Transverse - pathology; Myelitis, Transverse - virology; Post-infectious myelitis; SARS-CoV-2; Short Communication; COVID-19; Myelitis; SARS-CoV-2; MOG-IgG; Post-infectious myelitis
• ISSN: 0165-5728; 1872-8421; 1872-8421
• DOI: 10.1016/j.jneuroim.2021.577739

We report the case of a patient with symptoms of myelopathy following acute SARS-CoV-2 infection. MRI documented a longitudinally extensive transverse myelitis and further investigation was unremarkable with the exception of positivity for MOG-IgG in serum. This report extends the spectrum of post-COVID-19 neurological syndromes, and documents a very significant improvement to long-term oral corticosteroid therapy in this setting. Further prospective studies are needed to establish the risk of recurrence in this subset of patients. [Display omitted] •SARS-CoV-2 associated neuroimmune syndromes are rare but highly debilitating.•Post/para infectious myelitis is typically a longitudinally extensive transverse myelitis.•MOG-IgG positivity in low titers is of unknown significance.•Due to uncertain prognosis, long-term immunosuppression may be warranted.